Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Wow! What a surprise!
Deeply honored to receive the Indo-American-Cancer-Association (IACA) Award at American Society of Clinical Oncology (ASCO) 2026 annual meeting Chicago, 2026 for Outstanding Contributions to Drug Development and Pioneering Advances in Clinical Cancer Research.
- This recognition means so much not just as a personal milestone, but as a reflection of the incredible VILLAGE that makes this work possible
- Mentors who shaped My thinking and collaborators who challenged and inspired me and Patients who trusted me with their care and friends and family who anchored me through it all.
- Thank you to the IACA leadership for this honor Swaminathan P Iyer, Sant Chawla MD, Sant Chawla, Vinay Jain, Manmeet Ahluwalia, MD, MBA, FASCO, Sewa Legha, Sewanti Limaye, MBBS, MD, MS, Siddhartha Mukherjee, Jame Abraham, M.D. FACP, Neeraj Agarwal, MD, FASCO, Sumanta Pal, MD, FASCO, Ravi Salgia, Dr. Raja T.”
Other articles featuring Vivek Subbiah on OncoDaily.